RTP Mobile Logo
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation in Cervical and Endometrial Cancer (Webinar Video Proceedings)
Released June 2022

Featuring perspectives from Ms Paula Anastasia, Dr Robert Coleman, Dr David O’Malley and Ms Jaclyn Shaver. Published June 24, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cervical and endometrial cancers.

    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with cervical and endometrial cancers.


    • Understand the importance of microsatellite instability (MSI) testing for patients with endometrial cancer, and describe the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or mismatch repair deficient disease.
    • Review the biologic rationale for combining anti-PD-1/PD-L1 antibodies with agents targeting the VEGF pathway, and counsel patients regarding the effectiveness of this novel strategy for advanced, recurrent endometrial cancer that is not MSI high or mismatch repair deficient.
    • Evaluate the efficacy and safety of anti-PD-1 antibodies as monotherapy or in combination with platinum-based chemotherapy for patients with metastatic cervical cancer, and use this information to educate patients about the benefits and risks associated with these approaches.
    • Recognize the incidence of tissue factor expression in patients with cervical cancer, and consider the current role of novel agents designed to exploit this therapeutic target.
    • Assess the toxicities associated with immune checkpoint inhibitors and other novel agents used for the treatment of cervical or endometrial cancer, and offer patients supportive management strategies to minimize and ameliorate these side effects.
    • Describe the scientific justification for, published research data with and toxicity profiles of novel agents and strategies under investigation for endometrial or cervical cancer, and use this information to discuss clinical trial opportunities for eligible patients.

    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    This educational activity for 1.75 contact hours is provided by RTP during the period of June 2022 through June 2023.

    This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/ONS2022/Cervical-Endometrial/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONS2022Endometrial/NCPD.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Paula J Anastasia, MN, RN, AOCN
    GYN Oncology Advanced Practice Nurse
    University of California, Los Angeles
    Los Angeles, California

    Advisory Committee and Consulting Agreement: Merck; Speakers Bureau: Genentech, a member of the Roche Group, Seagen Inc.

    Robert L Coleman, MD
    Chief Scientific Officer
    US Oncology Research
    Gynecologic Oncology
    The Woodlands, Texas

    Advisory Committee: Agenus Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Novartis, OncXernaTherapeutics Inc, Onxeo; Consulting Agreements: AbbVie Inc, Agenus Inc, Alkermes, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, Gradalis Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Myriad Genetic Laboratories Inc, Novartis, OncXerna Therapeutics Inc, Onxeo, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Novartis; Data and Safety Monitoring Board/Committee: GOG Foundation Inc, VBL Therapeutics; Employment: Texas Oncology.

    David M O'Malley, MD
    Division Director, Gynecologic Oncology
    The Ohio State University and The James Cancer Center
    Columbus, Ohio

    Funding for Clinical Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, Merck Serono, Mersana Therapeutics Inc, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Sumitomo Dainippon Pharma Oncology Inc, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc, Yale University; Personal Fees (Consulting and/or Advisory Boards): AbbVie Inc, Ambry Genetics, Amgen Inc, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Celsion Corporation, Clovis Oncology, Corcept Therapeutics, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Diagnostics MSA, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Toray; Personal Fees: Agenus Inc, Myriad Genetic Laboratories Inc, Rubis, Tarveda Therapeutics.

    Jaclyn Shaver, MS, APRN, CNP, WHNP
    Section of Gynecologic Oncology
    Stephenson Cancer Center
    OU Health
    Oklahoma City, Oklahoma

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genmab and Seagen Inc, and GlaxoSmithKline.

    Release date: June 2022
    Expiration date: June 2023

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):